EICHORCondition: Ulcerative Colitis · Sponsor: Eli Lilly and Company
The purpose of this study is to evaluate the safety and efficacy of Mirikizumab in participants with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to, loss of response, or intolerant to conventional or biologic therapy for UC.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Digestive Health Specialists of the Southeast | Dothan, Alabama, United States | — |
| Dcr-Pi, Pc | Litchfield Park, Arizona, United States | — |
| Maricopa Integrated Health System | Phoenix, Arizona, United States | — |
| Physicians Research Group | Tempe, Arizona, United States | — |
| Yuma Gastro LLC | Yuma, Arizona, United States | — |
| Valley Gastroenterology | Arcadia, California, United States | — |
| Care Access Research | Berkeley, California, United States | — |
| Citrus Valley Health Partners | Covina, California, United States | — |
| Valley View Internal Medicine | Garden Grove, California, United States | — |
| Om Research, LLC | Lancaster, California, United States | — |
| Catalina Research Institute, LLC | Montclair, California, United States | — |
| California Medical Research Associates | Northridge, California, United States | — |
+ 490 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03518086